Ion channels and epilepsy;Canales ionicos y epilepsia

Revista de Neurologia

Volumn 30, Issue SUPPL. 1, 2000, Pages

  Armijo, J A ^a   De Las Cuevas, I ^a   Adin J ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Antiepileptic drugs; Channelopathies; Epilepsy; Ion channels

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; 6,7,8,9 TETRAHYDRO 5 NITROBENZ[G]INDOLE 2,3 DIONE 3 OXIME; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL; CARBAMAZEPINE; CHLORIDE CHANNEL; DIZOCILPINE; ETHOSUXIMIDE; FELBAMATE; FLUNARIZINE; GABAPENTIN; ION CHANNEL; LAMOTRIGINE; LIDOCAINE; LOSIGAMONE; MEMANTINE; OXCARBAZEPINE; PENTOBARBITAL; PHENYTOIN; POTASSIUM CHANNEL; PRIMIDONE; PROGABIDE; RALITOLINE; REMACEMIDE; RETIGABINE; RILUZOLE; SODIUM CHANNEL; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; ZONISAMIDE; 4 AMINOBUTYRIC ACID RECEPTOR; AMPA RECEPTOR; LIGAND; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC RECEPTOR;

ABSENCE; BENIGN CHILDHOOD EPILEPSY; CONFERENCE PAPER; DRUG TARGETING; EPILEPSY; EPILEPTOGENESIS; FRONTAL LOBE EPILEPSY; HAPPY PUPPET SYNDROME; HUMAN; HYPERPOLARIZATION; LONG QT SYNDROME; MYOKYMIA; ANIMAL; GENE EXPRESSION; GENETICS; KINDLING; METABOLISM; MOUSE; POINT MUTATION; REVIEW;

ANGELMAN SYNDROME; ANIMALS; ANTICONVULSANTS; CALCIUM CHANNELS; CHLORIDE CHANNELS; EPILEPSY; GENE EXPRESSION; HUMANS; ION CHANNELS; KINDLING, NEUROLOGIC; LIGANDS; LONG QT SYNDROME; MICE; POINT MUTATION; POTASSIUM CHANNELS; RECEPTORS, AMPA; RECEPTORS, GABA; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NICOTINIC; SODIUM CHANNELS;

EID: 0033931056     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Engel J, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven; 1997.
2. Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999.
3. Eadie MJ, Vajda FJE. Antiepileptic drugs pharmacology and therapeutics. Berlin: Springer; 1999.
4. Meldrum BS. Current strategies for designing and identifying new antiepileptic drugs. In Engel J, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven; 1997. p. 1405-16.
5. Dichter MA. Mechanisms of action of new antiepileptic drugs. In French J, Leppik I, Dichter MA, eds. Antiepileptic drug development. Advances in neurology. Vol. 76. Philadelphia: Lippincott-Raven; 1998. p. 1-9.
6. Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ. New waves of research in the epilepsies: crossing into the third millennium. In Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999. p. 3-58.
7. Taylor CP. Mechanisms of new antiepileptic drugs. In Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999. p. 1011.
8. Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ. Introduction to the idiopathic epilepsies. In Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999. p. 219-25.
9. Hess EJ. Migraines in mice? Cell 1996; 87: 1149-51.
10. Rho JM, Chugani HT. Alternating hemiplegia of childhood: insights into its pathophysiology. J Child Neurol 1998; 13: 39-45.
11. Leppert M, Anderson VE, Quattlebaum T, Stauffer D, O'Connell P, Nakamura Y, et al. Benign familial neonatal convulsions linked to genetic markers on chromosome 20. Nature 1989; 337: 647-8.
12. Berkovic SF. Genetics of epilepsy syndromes. In Engel J, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven; 1997. p. 217-24.
13. Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 1998; 18: 25-9.
14. Lewis TB, Leach RJ, Ward K, O'Connell P, Ryan SG. Genetic heterogeneity in benign familial neonatal convulsions: identification of a new locus on chromosome 8q. Am J Hum Genet 1993; 53: 670-5.
15. Charlier C, Singh NA, Ryan SG, Lewis TB, Reus BE, Leach RJ, et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet 1998; 18: 53-5.
16. Delgado-Escueta AV, Medina MT, Serratosa JM, et al. Mapping and positional cloning of common idiopathic generalized epilepsies: juvenile myoclonus epilepsy and childhood absence epilepsy. In Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999. p. 351-74.
17. Elmslie FV, Rees M, Williamson MP, Kerr M, Kjeldsen MJ, Pang KA, et al. Genetic mapping of a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q. Hum Mol Genet 1997; 6: 1329-34.
18. Sander T, Hildmann T, Kretz R, Furst R, Sailer U, Bauer G, et al. Allelic association of juvenile absence epilepsy with a gluR5 kainate receptor gene (GRIK1) polymorphism. Am J Med Genet 1997; 74: 416-42.
19. Wallace RH, Wang DW, Singh R, Scheffer IE, George AL, Phillips HA, et al. Febrile seizures and generalized epilepsy associated with a mutation in the Na(+)-channel beta-1 subunit gene SCN1B. Nat Genet 1998; 19: 366-70.
20. Phillips HA, Scheffer IE, Berkovic SF, Hollway GE, Sutherland GR, Mulley JC. Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q13.2. Nat Genet 1995; 10: 117-8.
21. Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha-4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995; 11: 201-3.
22. Phillips HA, Scheffer IE, Crossland KM, Bhatia KP, Fish DR, Marsden CD, et al. Autosomal dominant nocturnal frontal-lobe epilepsy: genetic heterogeneity and evidence for a second locus at 15q24. Am J Hum Genet 1998; 63: 1108-16.
23. Noebels JL, Rees M, Gardiner RM. Molecular genetics and epilepsy genes. In Engel J, Pedley TA, eds. Epilepsy: a comprehensive text-book. Philadelphia: Lippincott-Raven; 1997. p. 211-6.
24. Berkovic SF, Steinlein OK. Genetics of partial epilepsies. In Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999. p. 375-81.
25. Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 1997; 15: 70-3.
26. Matsuura T, Sutcliffe JS, Fang P, Galjaard RJ, Jiang Y, Benton CS, et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet 1997; 15: 74-7.
27. Wagstaff J, Knoll JHM, Fleming J, Kirkness EF, Martín-Gallardo A, Greenberg F, et al. Localization of the gene encoding the GABA(A) receptor beta-3 subunit to the Angelman/Prader-Willi region of human chromosome 15. Am J Hum Genet 1991; 49: 330-7.
28. Lubbers WJ, Brunt ERP, Scheffer H, Litt M, Stulp R, Browne DL, et al. Hereditary myokymia and paroxysmal ataxia linked to chromosome 12 is responsive to acetazolamide. J Neurol Neurosurg Psychiatry 1995; 59: 400-5.
29. Browne DL, Gancher ST, Nutt JG, Brunt ERP, Smith EA, Kramer P, et al. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nat Genet 1994; 8: 136-40.
30. Adelman JP, Bond CT, Pessia M, Maylie J. Episodic ataxia results from voltage-dependent potassium channels with altered functions. Neuron 1995; 15: 1449-54.
31. Keating MT. The long QT syndrome: a review of recent molecular genetic and physiologic discoveries. Medicine (Baltimore) 1996; 75: 1-5.
32. Ackerman MJ. The long QT syndrome: ion channel diseases of the heart. Mayo Clin Proc 1998; 73: 250-69.
33. Pacia SV, Devinsky O, Luciano DJ, Vázquez B. The prolonged QT syndrome presenting as epilepsy: a report of two cases and literature review. Neurology 1994; 44: 1408-10.
34. Mikati MA, Maguire H, Barlow CF, et al. A syndrome of autosomal dominant alternating hemiplegia. Clinical presentation mimicking intractable epilepsy; chromosomal studies and physiologic investigations. Neurol 1992; 42: 2251-7.
35. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutation in the Ca2+ gene CACNL1A4. Cell 1996; 87: 543-52.
36. Noebels JL. Single-gen models of epilepsy. In Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999. p. 227-38.
37. Toth M, Tecott L. Transgenic approaches to epilepsy. In Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999. p. 291-6.
38. Brusa R, Zimmermann F, Koh, DS, Feldmeyer D, Gass P, Seeburg PH, et al. Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. Science 1995; 270: 1677-80.
39. Olsen RW, Avoli M. GABA and epileptogenesis. Epilepsia 1997; 38: 399-407.
40. Chapman A, Meldrum B. Excitatory amino acids in epilepsy and novel antiepileptic drugs. In Pisani F, Perucca E, Avanzini G, Richens A, eds. New antiepileptic drugs. Amsterdam: Elsevier; 1991. p. 39-48.
41. Prince HK, Conn PJ, Blackstone CD, Huganir RL, Levey AI. Down-regulation of AMPA receptor subunit GluR2 in amygdaloid kindling. J Neurochem 1995; 64: 462-5.
42. Rogawski MA. Mechanism-specific pathways for new antiepileptic drug discovery. In French J, Leppik I, Dichter MA, eds. Antiepileptic drug development. Advances in neurology. Vol. 76. Philadelphia: Lippincott-Raven; 1998. p. 11-27.
43. Dichter MA, Wilcox KS. Excitatory synaptic transmission. In Engel J, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven; 1997. p. 251-63.
44. Rogawski MA, Donevan SD. AMPA receptors in epilepsy and as targets for antiepileptic drugs. In Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999. p. 947-64.
45. Meldrum BS, Chapman AG. Excitatory amino acid receptors and antiepileptic drug development. In Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999. p. 965-78.
46. Papazian DM, Bezanilla F. Voltage-dependent activation of ion channels. In Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999. p. 481-91.
47. Catterall WA. Molecular properties of brain sodium channels: an important target for anticonvulsant drugs. In Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999. p. 441-56.
48. Bertrand D, Changeux JP. Nicotinic receptor: a prototype of allosteric ligand-gated ion channels and its possible implications in epilepsy. In Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999. p. 171-88.
49. Jackson MB. Ligand-gated channel: postsynaptic receptors and drug targets. In Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999. p. 511-24.
50. Sprengel R, Higuchi M, Monyer H, Seeburg PH. Glutamate receptor channels: a possible link between RNA editing in the brain and epilepsy. In Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999. p. 525-34.
51. Rogers SW, Andrews I, Gharing LC, Whisenand T, Cauley K, Crain B, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994; 265: 648-51.
52. Olsen RW, DeLorey TM, Gordey M, Kang MH. GABA receptor function and epilepsy. In Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999. p. 499-510.
53. Snead III OC, Depaulis A, Vergnes M, Marescaux C. Absence epilepsy: advances in experimental animal models. In Delgado-Escueta AV, Wilson WA, Olsen RW, Porter RJ, eds. Jasper's basic mechanisms of the epilepsies. Advances in neurology. Vol. 79. 3 ed. Philadelphia: Lippincott-Williams & Wilkins; 1999. p. 253-78.
54. Flórez J. Acciones de los fármacos II. Mecanismos moleculares. En Flórez J, ed. Farmacología humana. 3 ed. Barcelona: Masson; 1997. p. 17-45.
55. Flórez J, Pazos A. Neurotransmisión en el SNC. En Flórez J, ed. Farmacología humana. 3 ed. Barcelona: Masson; 1997. p. 409-33.
56. Hurlé MA. Fármacos ansiolíticos y sedantes. En Flórez J, ed. Farmacología humana. 3 ed. Barcelona: Masson; 1997. p. 453-67.
57. Online Mendelian Inheritance in Man (OMIM). National Center for Biotechnology Information. Johns Hopkins University [www.ncbi.nlm.nih.gov/omim].